Effective elimination of liver cancer stem-like cells by CD90 antibody targeted thermosensitive magnetoliposomes
Metrics: PDF 952 views | HTML 2146 views | ?
Rui Yang1, Li Y. An2, Qin F. Miao1, Feng M. Li1, Yong Han1, Hui X. Wang1, Dang P. Liu1, Rong Chen3 and Sha Q. Tang1
1 School of Medicine, Southeast University, Nanjing, People’s Republic of China
2 Jiangsu Key Laboratory of Molecular and Fuctional Imaging, Department of Radiology, Zhongda Hospital, Nanjing, People’s Republic of China
3 Department of Oncology, Zhongda Hospital, Nanjing, People’s Republic of China
Sha Q. Tang, email:
Keywords: LCSCs; CD90; TMs; targeting therapy; hyperthermia therapy
Received: December 02, 2015 Accepted: April 16, 2016 Published: April 29, 2016
Aim: To investigate the use of thermosensitive magnetoliposomes (TMs) loaded with magnetic iron oxide (Fe3O4) and the anti-cancer stem cell marker CD90 (CD90@TMs) to target and kill CD90+ liver cancer stem cells (LCSCs).
Methods: The hepatocellular carcinoma cell line Huh7 was used to separate CD90+ LCSCs by magnetic-activated cell sorting. CD90@TMs was characterized and their ability to target CD90+ LCSCs was determined. Experiments were used to investigate whether CD90@TMs combined with magnetic hyperthermia could effectively eliminate CD90+ LCSCs.
Results: The present study demonstrated that CD90+ LCSCs with stem cells properties were successfully isolated. We also successfully prepared CD90@TMs that was almost spherical and uniform with an average diameter of 130±4.6 nm and determined that magnetic iron oxide could be incorporated and retained a superparamagnetic response. CD90@TMs showed good targeting and increased inhibition of CD90+ LCSCs in vitro and in vivo compared to TMs.
Conclusion: CD90@TMs can be used for controlled and targeted delivery of anticancer drugs, which may offer a promising alternative for HCC therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.